Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ian Gaddie

Optometrist, Corneal and Contact Management Louisville, KY Doctor of Optometry

NPI 1053385476 CMS profile 319622

7635 Shelbyville Rd, Louisville, KY 40222

Open in the dashboard

General payments

$856,533

958 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$26,521 paid to institutions, not to them · program year 2019

Through program year 2025, Ian Gaddie of Louisville, KY is reported in the CMS Open Payments database as having received $856,533 across 958 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $26,521 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Optometrist, Corneal and Contact Management profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $254,429 250
2024 General $138,979 186
2023 General $53,802 99
2022 General $77,697 59
2021 General $74,812 99
2020 General $111,888 100
2019 General $144,926 165

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ian Gaddie
  • Optometrist, Corneal and Contact Management median
  • Middle half of Optometrist, Corneal and Contact Management
  • National median

In program year 2025, general payments to Ian Gaddie were reported at $254,429. Among 618 Optometrist, Corneal and Contact Management profiles paid that year, the median was $227 and the middle half received between $95 and $604.

Show as a table
Year Ian Gaddie Optometrist, Corneal and Contact Management median Middle half National median
2019 $144,926 $203 $84–$530 $163
2020 $111,888 $88 $35–$234 $114
2021 $74,812 $143 $54–$353 $132
2022 $77,697 $167 $65–$422 $149
2023 $53,802 $195 $76–$549 $160
2024 $138,979 $202 $85–$523 $164
2025 $254,429 $227 $95–$604 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tarsus Pharmaceuticals, Inc. $207,847 208 payments
  2. Bausch & Lomb Americas Inc. $183,053 159 payments
  3. Bausch & Lomb, a division of Bausch Health US, LLC $127,369 93 payments
  4. Allergan Inc. $67,111 106 payments
  5. Aerie Pharmaceuticals, Inc. $49,350 43 payments
  6. Harrow Eye, LLC $49,160 51 payments
  7. Sun Pharmaceutical Industries Inc. $29,292 39 payments
  8. AbbVie, Inc. $25,494 32 payments
  9. Topcon Medical Systems, Inc. $20,445 26 payments
  10. Sight Sciences, Inc. $17,554 42 payments
  11. Other $79,858 159 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $273,226 143 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $235,130 76 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $115,650 37 payments
  4. Travel and Lodging $85,596 217 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $65,900 14 payments
  6. Honoraria $50,975 21 payments
  7. Food and Beverage $30,056 450 payments
Products named General payments · program years 2019–2025
  1. XDEMVY $180,789 184 payments
  2. BIOTRUE $126,599 30 payments
  3. VYZULTA $94,023 94 payments
  4. ULTRA $78,053 29 payments
  5. VEVYE $48,358 36 payments
  6. MIEBO $39,845 48 payments
  7. Cequa $28,065 36 payments
  8. rhopressa $25,548 12 payments
  9. rocklatan Glaucoma $25,548 12 payments
  10. Rocklatan Glaucoma $23,794 30 payments
  11. Other $262,262 480 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

596

Median for Optometry: 120

Drug cost

$265,457

Median for Optometry: $8,864

Branded share of claims

75.2%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 164 $91,213
Xdemvy Lotilaner Brand 43 $78,918
Combigan Brimonidine Tartrate/Timolol Brand 72 $24,422
Vyzulta Latanoprostene Bunod Brand 51 $20,304
Rocklatan Netarsudil Mesylat/Latanoprost Brand 21 $18,657
Restasis Cyclosporine Brand 15 $15,719
Rhopressa Netarsudil Mesylate Brand 14 $8,087
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 26 $5,074
Prednisolone Acetate Generic 29 $876
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 42 $819

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$23,824

Medicare's payments for the services billed

Medicare patients

157

Average age 77

Services billed

512

80 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 38%
Diabetes 29%
Ischemic heart disease 24%
Cancer 18%
Atrial fibrillation 17%
Depression 15%
Chronic kidney disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $45,217
$45,217 43 —
VEVYE
  • Harrow Eye, LLC $13,649
$13,649 — —
LUMIGAN
  • AbbVie, Inc. $8,828
$8,828 164 —
VYZULTA
  • Bausch & Lomb Americas Inc. $6,935
$6,935 51 —
MIEBO
  • Bausch & Lomb Americas Inc. $4,685
$4,685 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

958 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist, Corneal and Contact Management in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record